Latest News

Historically, dulaglutide was a preferred choice because it was proven to reduce major adverse cardiovascular events in the REWIND trial.

Ivermectin, fenbendazole, and mebendazole have gained traction as alternative cancer therapies despite a lack of clinical evidence.

The RECOVER-AUTONOMIC trial underscores the necessity of better clinical end points to assess interventions in the long COVID population.

CHAMPION-AF may potentially lead to a shared decision-making process between a lifetime of medication and a one-time catheter-based procedure.

In a session at the American Pharmacists Association Annual Meeting, Craig Beavers, PharmD, provided practical insights for pharmacist to optimize the care of patients with cardio-kidney-metabolic conditions.

The FDA removed the age requirement from the neffy 1 mg label, allowing use based solely on weight and expanding access to younger pediatric patients at risk for anaphylaxis.

Pharmacists at the 2026 HOPA Annual Meeting discuss medical misinformation and how to combat it.

CDC flags a late respiratory syncytial virus (RSV) rise, while the NFID urges spring vigilance, vaccines, and monoclonals to protect infants and older adults from this virus.

Volunteer service strengthens pharmacists’ empathy, confidence, and communication, boosting patient trust, teamwork, and community connection.

Insulin icodec-abae injection becomes the first and only once-weekly basal insulin option, offering personalized care for adults with type 2 diabetes (T2D).

Experts discuss the 340B Pricing Program, sharing updates, ongoing challenges, and solutions for pharmacists.

ABBV-744 BD2-selective BET inhibitor shows early spleen and symptom gains with manageable cytopenias in a phase 1b trial.

FDA ramps up action on compounded GLP‑1 weight‑loss drugs, targeting telehealth ads as Novo sues Hims & Hers and regulators hint at seizures.

Late-stage Lyme disease vaccine candidate VLA15 boosts immunization hopes as tick infections rise.

Tarlatamab, a DLL3 T‑cell engager, advances treatment of extensive‑stage SCLC.

Insights from the 2026 HOPA Annual Conference highlight the pharmacist's role in operationalizing belantamab mafodotin.

The approval is a milestone for rare disease that has lacked treatments capable of crossing the blood-brain barrier and introduces a new class of agent that pharmacists will need to understand.

The indication is for patients who have received 1 to 3 prior systemic treatment regimens, of which at least 1 includes bevacizumab.

Albuminuria (uACR) flags early vascular damage linking chronic kidney disease and cardiovascular risk.

Independent pharmacies produce some of health care’s most valuable data, yet much of the profit and power they create bypasses the pharmacies entirely.